퍼스널리스 (PSNL) 주가

퍼스널리스(PSNL)는 NASDAQ에 상장된 Healthcare · Diagnostics & Research 기업입니다. 현재가 $16.33 (+0.62%), 시가총액 $0.74B, 52주 최저~최고 $4.41 ~ $11.25.

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to

핵심 지표

• 현재가: $16.33 (+0.62%)
• 시가총액: $0.74B
• 52주 최저~최고: $4.41 ~ $11.25
• 섹터: Healthcare
• 산업: Diagnostics & Research
• 거래소: NASDAQ

퍼스널리스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

퍼스널리스 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4.4286

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 2.76
• 순이익률: -1.48%
• 영업이익률: -2.08%

자주 묻는 질문